Real-world access and barriers to CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a population-based study.
Two-thirds of patients with relapsed lymphoma accessed CAR-T cell therapy in a public Canadian program with strong survival rates, showing that access barriers are medical fit rather than geographic.
In a population-based cohort from a publicly funded Canadian provincial program, approximately two-thirds of R/R DLBCL patients initiating 2L/3L+ therapy accessed CAR-T with favorable real-world outcomes (12-month OS 81%). Crucially, the main barriers were poor PS, age/frailty, and uncontrolled disease rather than geographic or socioeconomic factors, contrasting with US estimates of <30% access rates.
What the study was
- Study design
- Retrospective population-based cohort study
- Category
- Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
- Maturity
- Validated
- Journal
- Transplant Cell Ther
Why it surfaced
Novel real-world data quantifying CAR-T access and barriers in a universal healthcare system; population-based design avoids referral bias; University of Calgary and University of Alberta; important benchmark for publicly funded CAR-T programs globally. Addresses clinically urgent question of CAR-T access equity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.